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Abstract
Background Among the proteinuric patients with chronic
kidney disease (CKD) who undergo a renal biopsy, we
sometimes encounter those who cannot be classified as
having a known primary or secondary glomerular disease.
The pathogenesis and pathophysiology of these CKD
patients have not been sufficiently elucidated.
Methods We recruited 34 proteinuric patients without
known glomerular diseases. The glomerular volumes (GV)
of the biopsy specimens from those patients were deter-
mined by a morphometric analysis. Glomerular hypertro-
phy (GH) was defined as having more than 3.6 9 106 lm3.
The patients were divided in two groups: those with GH
(Group 1) and those without GH (Group 2). We compared
the clinical and pathological parameters between Group 1
and Group 2, and among the three groups of patients: non-
obese, overweight and obese group.
Results The patients with Group 1 had significantly
higher values for the proportion of males, the body mass
index (BMI), uric acid and significantly lower values for
the glomerular density (GD). Of note, a multivariate
regression analysis revealed that sex, the BMI and GD
were significant factors correlated with the mean GV. The
values for the mean GV were significantly higher in the
overweight and obese groups as compared to the non-obese
group, and the values for the GD were significantly lower
in the obese group than in the non-obese group.
Conclusions We identified a subgroup of patients who
were characterized as having a high BMI and GV, and a
low GD among the proteinuric CKD patients without
known glomerular diseases.
Keywords Chronic kidney disease  Glomerular
hypertrophy  Proteinuria  Overweight  Obesity 
Body mass index  Renal biopsy  Glomerular density
Introduction
Chronic kidney disease (CKD) is a worldwide public health
problem [1, 2]. It has been reported that the prevalence of
CKD is 13 % in the United States [3], 10–13 % in Euro-
pean countries [4, 5], 13 % in Japan [6] and 12–13 % in
China [7]. Of all CKD patients, those with proteinuria have
been shown to have a higher risk of developing cardio-
vascular disease (CVD) [8], as well as end-stage renal
disease (ESRD) [9]. Although a renal biopsy is a useful
diagnostic procedure to elucidate the pathogenesis in pro-
teinuric patients, we sometimes encounter those who do not
fit the diagnostic criteria for any known primary or sec-
ondary glomerular diseases. The pathogenesis and patho-
physiology of these CKD patients have not been
sufficiently elucidated.
On the other hand, previous experimental and clinical
studies demonstrated that glomerular hypertrophy (GH)
plays an important role in the progression of glomerular
injury [10, 11]. We recently reported that a low glomerular
density (GD) associated with GH might be a characteristic
histological finding of patients with obesity-related glo-
merulopathy (ORG) [12]. We hypothesized that the GD,
GH and obesity could be the characteristic findings of the
proteinuric CKD patients without known glomerular
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diseases. To investigate this hypothesis, we carried out an
investigation to explore the pathogenic role of GD, the
glomerular volume (GV) and obesity in those patients.
Subjects and methods
Patient selection
Of the 990 Japanese patients who underwent a renal biopsy
at our institute from 1995 through 2000, because they
presented with persistent urine abnormalities, such as
proteinuria, we excluded 947 patients with known primary
or secondary glomerular diseases, i.e., minimal change
nephrotic syndrome, focal glomerulosclerosis (FGS) pre-
senting with nephrotic syndrome and immunoglobulin (Ig)
A nephropathy, membranous nephropathy, poststrepto-
coccal acute glomerulonephritis, membranoproliferative
nephritis, lupus nephritis, anti-glomerular basement mem-
brane antibody nephritis, monoclonal Ig-deposition disease
and other glomerulonephritis accompanied by Ig deposits,
diabetic nephropathy, anti-neutrophil cytoplasmic anti-
body-related nephritis, amyloid nephropathy, pre-eclamp-
sia or pregnancy-induced hypertension, thin basement
membrane disease and Alport’s syndrome. Furthermore, of
the remaining adult 43 cases without known glomerular
diseases, 9 patients having estimated glomerular filtration
rate (eGFR)\60 ml/min/1.73 m2 at the time of the biopsy
were excluded because of the probability of renal func-
tional compensation, leaving 34 patients (Fig. 1).
Pathological investigation
All tissue samples were collected by percutaneous needle
biopsy. An 18-gauge biopsy needle was used for all
biopsy cases in this study. After the tissue was embedded
in paraffin, it was finely sliced into 3–4 lm sections.
Hematoxylin–eosin staining, periodic acid–Schiff (PAS)
staining, Masson-trichromium staining and periodic acid–
methenamine silver (PAM) staining were performed. We
evaluated the presence or absence of exhibiting global
glomerulosclerosis, segmental glomerulosclerosis, cellular
crescents, fibrocellular crescents, fibrous crescents or tuft
adhesion. We also evaluated the presence or absence of an
increased mesangial matrix. We semiquantified and eval-
uated the interstitial fibrosis and the extent of tubular
atrophy according to the proportion of the total cortical
area exhibiting fibrosis, and scored them as follows: 0,
none; 1?, 1–25 %; 2?, 26–50 % and 3?, C50 %. We
scored and evaluated the intimal hyalinization of the
arterioles and intimal thickness of theinterlobular arteries
as follows: 0, no lesions; 1?, mild; 2?, moderate and 3?,
severe.
The GD was determined by calculating the number of
glomeruli excluding globally sclerosed glomeruli per total
renal cortical area and was measured using a computed
imaging analyzer (Leica IM500, Leica Microsystems,
Germany). The glomerular area (GA) was defined as the
area described by the outer capillary loops of the tuft using
the computed imaging analyzer. The GA was measured in
only one slice of the tissue section to avoid multiple
measurements of the same glomeruli. The mean GA was
calculated by averaging the areas of all the glomeruli. The
mean glomerular volume (GV) was calculated from the
measured GA according to the equation:
GV ¼ ðGAÞ3=2  b=d;
Fig. 1 A flow diagram of patients considered for inclusion. Of the
990 Japanese patients with persistent urine abnormalities, such as
proteinuria, who underwent a renal biopsy at our institute from 1995
through 2000, we excluded 947 patients with known primary or
secondary glomerular diseases. Furthermore, of the remaining adult
43 cases, 9 patients having estimated glomerular filtration rate (eGFR)
\60 ml/min/1.73 m2 at the time of the biopsy were excluded because
of the probability of renal functional compensation, leaving 34
patients. * Minimal change nephrotic syndrome, FGS presenting with
nephrotic syndrome and IgA nephropathy, membranous nephropathy,
poststreptococcal acute glomerulonephritis, membranoproliferative
nephritis, lupus nephritis, anti-glomerular basement membrane
antibody nephritis, monoclonal Ig-deposition disease and other
glomerulonephritis accompanied by Ig deposits, diabetic nephropa-
thy,anti-neutrophil cytoplasmic antibody-related nephritis, amyloid
nephropathy, pre-eclampsia or pregnancy-induced hypertension, thin
basement membrane disease and Alport’s syndrome
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where b is a dimensionless shape coefficient (b = 1.38 for
spheres) and d is a size distribution coefficient used to
adjust for variations in glomerular size [13]. The analysis
used d = 1.01, as in previous studies [14, 15].
Definition of a hypertrophied glomerulus
We previously analyzed the renal biopsy specimens from 20
kidney transplant donors as controls [12]. Kidney transplant
donors represented the healthy individuals without apparent
CKD. Their mean GV ± the standard deviation (SD) was
2.4 ± 0.6 9 106/lm3. The mean GV ? 2 SD for the
donors was 3.6 9 106 lm3, which covered approximately
95 % of the donors’ GV values. Therefore, in the present
study, a hypertrophied glomerulus was defined as one
having a GV more than 3.6 9 106 lm3. We separated the
patients into two groups; Group 1 consisted of patients with
mean GV C3.6 9 106 lm3 (those with GH, n = 19), and
Group 2 consisted of patients with mean GV \3.6 9 106
lm3 (those without GH, n = 15).
Items included in the clinical examination
The following blood parameters were measured in all
patients: the levels of fasting blood glucose (FBG), serum
total cholesterol (TC), triglycerides (TG), high-density
lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C), creatinine (Cr) and uric acid (UA).
The urine parameter measured was the protein excretion
over a 24-h period. The estimated glomerular filtration rate
(eGFR) was calculated as follows: 194 9 serum Cr
level - 1.094 9 age - 0.287 (female = 90.739) [16]. To
use this equation, the serum Cr levels need to be measured
by an enzymatic method, which we applied in this study.
The 24-h urine protein level was measured by spectrome-
try. The body mass index (BMI) was calculated as the
weight (kg)/height (m2). The blood pressure was measured
using a standard mercury sphygmomanometer. The mean
arterial pressure (MAP) was defined as the diastolic pres-
sure plus a third of the systolic pressure. Hypertension was
defined as a systolic pressure over 140 mmHg or a diastolic
pressure over 90 mmHg, or use of antihypertensive medi-
cations. The patients who were using antihypertensive
medications, such as angiotensin blockers, for renoprotec-
tion despite normal blood pressure were considered to be
normotensive.
Statistical analyses
The continuous variables are expressed as the mean ± SD.
The variables were assessed for normality both visually
(normal probability plot) and by inferential statistics
(Kolmogorov–Smirnov tests and Bartlett test). The clinical
findings at the time of the biopsies for Group 1 and Group 2
were compared using Student’s t test and Fisher’s exact
probability test, and the pathological findings were com-
pared using Fisher’s exact probability test and the Mann–
Whitney U test. Non-parametric variables were expressed
as medians and interquartile ranges (IQR) and were com-
pared using the Mann–Whitney U test. Next, we examined
the correlations between the individual mean GV and the
clinical or pathological findings at the time of biopsy for all
34 cases, using the univariate regression analysis and the
stepwise multivariate regression analysis. The factors
associated with the mean GV in the univariate regression
analysis were selected for inclusion as the independent
valuables in the stepwise multivariate regression analysis.
We further analyzed these CKD patients’ kidney tissues to
investigate the effects of obesity on the GD and GV. We
compared the clinical and pathological variables among
three groups categorized according to the BMI: non-obese
(BMI \25 kg/m2), overweight (25 \ BMI B 30 kg/m2)
and obese (BMI C30 kg/m2). The Kruskal–Wallis test, the
one factor analysis of variance (ANOVA) and the Chi
squared test were applied for comparisons of the variations
among these three categories, and the Tukey–Kramer
method was used for multiple comparisons among them.
The StatView software program (SAS Institute Inc., Cary,
NC, USA), version 5.0, was used for all of the analyses.
Results
Comparison of the clinical and pathological findings
at biopsy between groups 1 and 2
As shown in Table 1, Group 1 had significantly higher
values for the proportion of males and hypertensive
patients, the BMI, MAP, TC, TG, Cr and UA, and signif-
icantly lower values for HDL-C. No significant difference
was found in the daily urine protein excretion between the
two groups. In comparison with Group 2, the patients in
Group 1 had significantly higher values for the number of
patients with globally sclerosed glomeruli and for the score
of patients with arteriolar hyalinosis, and significantly
lower values for GD (Table 2).
Clinical and pathological findings associated
with the mean GV
In the univariate regression analysis, the individual mean
GV was significantly associated with the BMI, sex, MAP,
Cr and UA at the time of the renal biopsy (Table 3).
Concerning the pathological parameters, the mean GV
was significantly associated with GD, as well as the
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degrees of globally sclerosed glomeruli, interstitial
fibrosis and arteriolar hyalinosis. The stepwise multiple
linear regression analyses were performed using the BMI,
sex, MAP, Cr, UA, GD, and the degrees of globally
sclerosed glomeruli, interstitial fibrosis and arteriolar
hyalinosis, as independent variables. The analyses
revealed that the BMI, sex and GD were significant
factors correlated with the mean GV.
Table 1 Clinical characteristics of patients with and without glomerular hypertrophy at the time of the renal biopsy
Group 1: patients with
glomerular hypertrophy (n = 19)
Group 2: patients without
glomerular hypertrophy (n = 15)
p value
Male (%) 94 40 0.002a
Age (years) 42 ± 9 42 ± 18 0.995b
BMI (kg/m2) 27 ± 3 22 ± 4 \0.001b
MAP (mmHg) 102 ± 12 87 ± 10 \0.001b
Hypertension (%) 58 20 0.038a
TC (mg/dl) 237 ± 59 196 ± 49 0.036b
TG (mg/dl) 216 ± 102 132 ± 90 0.018b
HDL-C (mg/dl) 46 ± 12 55 ± 10 0.045b
FBG (mg/dl) 96 ± 13 88 ± 22 0.269b
Cr (mg/dl) 0.8 ± 0.2 0.6 ± 0.2 0.046b
eGFR (ml/min/1.73 m2) 86.5 (74.5, 101.9) 100.2 (89.1, 121.8) 0.086c
UA (mg/dl) 7.3 ± 1.5 5.3 ± 1.5 \0.001b
Urinary protein excretion rate (g/day) 0.70 (0.40, 1.04) 0.41 (0.36, 0.61) 0.182c
Values are expressed as the percentage of patients, mean ± SD or medians [interquartile ranges (IQR)]
BMI body mass index, MAP mean arterial pressure, TC total cholesterol, TG triglycerides, HDL-C high-density lipoprotein cholesterol, FBG
fasting blood glucose, Cr creatinine, eGFR estimated glomerular filtration rate, UA uric acid
a Fisher’s exact probability test
b Student’s t test (mean ± SD)
c Mann–Whitney U test [median (IQR)]
Table 2 Renal histological findings of patients with and without glomerular hypertrophy
Group 1: patients
with glomerular
hypertrophy (n = 19)
Group 2: patients
without glomerular
hypertrophy (n = 15)
p value
Patients with globally sclerosed glomeruli 14 3 0.005a
Patients with segmentally sclerosed glomeruli 3 1 0.613a
Patients with increased mesangial matrix 3 focal segmental in 2 patients 1 focal segmental in a patient [0.999a
Score of patients with interstitial fibrosis 1(?) in 18 patients
2(?) in 1 patients
1(?) in 10 patients 0.060b
Score of patients with arteriolar hyalinosis 1(?) in 6 patients
2(?) in 8 patients
3(?) in 4 patients
1(?) in 3 patients
2(?) in 1 patients
3(?) in 2 patients
0.036b
Score of patients with increased arterial
fibrous intimal thickness
1(?) in 6 patients
2(?) in 3 patients
1(?) in 3 patients
2(?) in 2 patient
0.392b
GD 2.0 ± 0.7 3.3 ± 1.2 \0.001c
Values are expressed as the number of patients or mean ± SD
GD glomerular density excluding global glomerular sclerosis
a Fisher’s exact probability test
b Mann–Whitney U test
c Student’s t test
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Comparison of the different BMI categories
As shown in Table 4, the values for GD, as well as those
for the eGFR, were significantly different among the non-
obese, overweight and obese groups. The values for the
mean GV were also significantly different among these
three groups. The values for the mean GV were signifi-
cantly higher in the overweight and obese groups than in
the non-obese group, and the values for GD were signifi-
cantly lower in the obese group than in the non-obese
group.
Discussion
Our major goal was to clarify the pathogenic role of the
GD, GV and obesity in proteinuric CKD patients without
known glomerular diseases. When our 34 patients were
divided into two groups based on the presence or absence
of a mean GV which fulfilled the definition of GH (GV
[3.6 9 106 lm3), the patients with GH (Group 1) showed
significantly higher values for the BMI, MAP and UA, and
a significantly higher frequency of male patients compared
to those without GH (Group 2). Of note, the patients in
Group 1 had significantly lower GD values as compared to
Group 2 patients, whereas the degrees of other pathological
changes were comparable between the two groups, except
for the score of patients with arteriolar hyalinosis and the
frequency of patients with global sclerosed glomeruli
(Table 2). The stepwise multivariate regression analyses
for all 34 patients revealed that the GD, sex and BMI were
independent factors significantly associated with the mean
GV (Table 3).
Among the three subgroups of patients categorized
according to the BMI, i.e., non-obese (BMI \25 kg/m2),
overweight (25 \ BMI B 30 kg/m2) and obese (BMI
C30 kg/m2) patients, the GD values, as well as the eGFR,
were significantly lower in the groups with higher BMI
values. Thus, among our proteinuric CKD patients, we
could find a subgroup of patients who had higher BMI and
GV values and a lower GD, as common clinical and
pathological features.
There have been various investigations into the rela-
tionship between obesity and renal impairment [17, 18].
Kambham et al. [19] defined a new entity, ORG, in which
GH with FGS lesions or only GH developed in obese
patients with a BMI of 30 kg/m2 or more, and proposed
ORG as a renal disease that has been increasing in preva-
lence in recent years. These previous studies examined the
renal histological features of obese patients with a BMI of
30 kg/m2 or more. In contrast, the present study examined
Table 3 Clinical and pathological findings associated with mean GV
(univariate regression model and multivariate stepwise regression
model) (n = 34)
Univariate Multivariate
(stepwise)
r p value b p value
Sex 0.613 0.0001 0.371 \0.0001
BMI 0.638 \0.0001 0.366 \0.0001





Cr 0.426 0.0120 – –
eGFR -0.146 0.4089
UA 0.495 0.0047 – –
Urine protein excretion rate 0.054 0.7627
Degree of globally
sclerosed glomeruli






0.570 0.0004 – –
Degree of arteriolar
hyalinosis
0.430 0.0112 – –
Degree of arterial fibrous
intimal thickness
0.212 0.2373
GD -0.581 0.0003 -0.289 \0.0001
BMI body mass index, MAP the mean arterial pressure, TC total
cholesterol, TG triglyceride, HDL-C high-density lipoprotein cho-
lesterol, FBG levels of fasting blood glucose, Cr creatinine, eGFR the
estimated glomerular filtration rate, UA uric acid, GD glomerular
density excluding global glomerular sclerosis
Table 4 Clinical and histological findings of the patients categorized









Age (years) 38 (29, 49) 41 (37, 46) 50 (41, 54) 0.479a
Male (%) 46 80 100 0.066c
eGFR (ml/min/1.73 m2) 110 ± 26 91 ± 20 71 ± 9 0.015b
Histopathologic
GD (glomeruli/lm2) 3.3 ± 1.2 2.2 ± 1.0 1.8 ± 0.6 0.021b
Mean GV (9106/lm3) 2.4 ± 1.3 3.6 ± 0.9 4.7 ± 0.8 0.026b
Values are expressed as the percentage of patients, mean ± SD or median
[interquartile ranges (IQR)]
BMI body mass index, eGFR the estimated glomerular filtration rate, GD glo-
merular density excluding global glomerular sclerosis, mean GV mean glomerular
volume
 p \ 0.05 vs. non-obese by multiple comparisons using the Tukey–Kramer
method
a The Kruskal–Wallis test
b The one factor analysis of variance (ANOVA) test
c Chi square test
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the characteristics of proteinuric patients without known
primary or secondary glomerular diseases, especially
focusing on the glomerular volume in the kidney biopsy
specimens. We found that higher BMI levels, even if they
were \30 kg/m2, had a significant correlation with the
enlargement of the GV. Therefore, the present study was
unique in terms of the methodology, which was based on
the glomerular volume, not the BMI.
We recently reported that a low GD associated with GH
may be a characteristic histological finding of patients with
ORG [12]. In that study, the analysis of autopsy cases
without CKD, which were characterized by having an
eGFR C60 ml/min/1.73 m2 and no persistent urinary
abnormalities, showed that the GD in overweight or obese
persons was similar to that in non-obese individuals,
although the GV was larger in the overweight and obese
groups as compared to the non-obese group, among the
autopsy cases. In contrast to those results, we found in the
present study that the GD levels in our proteinuric patients
were significantly lower in the obese group as compared to
the non-obese group. In addition, the GD had a significant
inverse correlation with the GV in our 34 patients
(Table 3), indicating the functional adaptation of remaining
glomeruli in patients with a small number of functioning
nephrons. Based on these findings, it is plausible to spec-
ulate that, in the patients with a low GD and large GV,
obesity-related hemodynamic changes such as an increase
of plasma flow or blood pressure within the glomerulus can
alter glomerular permselectivity. Thus, a low GD may play
a crucial role in the development of proteinuria in associ-
ation with GH in overweight or obese persons.
Concerning the pathological findings of our 34 pro-
teinuric patients, the population of patients with increased
mesangial matrix was comparable between those with and
without GH (Table 2), indicating that GH was caused by the
enlargement of glomerular capillaries. Sasatomi et al. [20]
previously demonstrated, using glomerular morphometry,
that the GH observed in obese patients presenting with urine
abnormalities was due to the enlargement of glomerular
capillaries. This finding was consistent with our results
showing that there was no significant mesangial matrix
increase in the hypertrophied glomeruli.
There are several limitations of this study that should be
kept in mind when interpreting the results. First, it is
uncertain whether the GD on a renal biopsy specimen
represents the total nephron number of the whole kidney.
Therefore, the finding of a low GD observed in the patients
with GH may not necessarily reflect a low number of
glomeruli. Accurately determining the origin of the low
GD in the biopsy specimens of those with GH requires
further investigations. Second, there is a possibility that
some of the 34 patients might have had FGS without
nephrotic syndrome or benign nephrosclerosis, because
these two diseases could not be completely excluded
merely on the basis of the morphological findings. How-
ever, the possibility of the presence of FGS patients would
be considerably low, since only four patients (12 %) had
segmentally sclerosed glomeruli in this study. Some
patients with benign nephrosclerosis may also have been
enrolled in this study, since most of the patients with GH
had arteriolar hyalinosis. Nevertheless, it was meaningful
that the subpopulation of patients with benign nephro-
sclerosis could be identified by the characteristics of low
GD with GH on the biopsy specimens, if such cases had
been included in our study.
In summary, among the 34 proteinuric CKD patients
without known glomerular diseases, those with GH had
significantly lower GD compared to those without GH. The
BMI and GD values were identified as significant factors
that correlated with the mean GV. The values for the mean
GV were significantly higher in the overweight and obese
groups than in the non-obese group, and the values for the
GD were significantly lower in the obese group than in the
non-obese group. Thus, we could identify a subgroup of
patients who were characterized as having a high BMI and
GV and a low GD, among the proteinuric CKD patients
without known glomerular diseases.
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